Pim P van de Donk
Overview
Explore the profile of Pim P van de Donk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Sluis J, Boellaard R, Dierckx R, van Esch E, Croes D, de Ruijter L, et al.
Eur J Nucl Med Mol Imaging
. 2023 Mar;
50(8):2258-2270.
PMID: 36947185
Purpose: Monoclonal antibody (mAb)-based PET (immunoPET) imaging can characterise tumour lesions non-invasively. It may be a valuable tool to determine which patients may benefit from treatment with a specific monoclonal...
2.
de Ruijter L, van de Donk P, Hooiveld-Noeken J, Giesen D, Elias S, Lub-de Hooge M, et al.
Nat Med
. 2022 Dec;
28(12):2601-2610.
PMID: 36471036
Immune checkpoint inhibitors (ICIs), by reinvigorating CD8 T cell mediated immunity, have revolutionized cancer therapy. Yet, the systemic CD8 T cell distribution, a potential biomarker of ICI response, remains poorly...
3.
van de Donk P, Oosting S, Knapen D, van der Wekken A, Brouwers A, Lub-de Hooge M, et al.
J Immunother Cancer
. 2022 Aug;
10(8).
PMID: 35922089
The advent of immune checkpoint inhibitors has reinvigorated the field of immuno-oncology. These monoclonal antibody-based therapies allow the immune system to recognize and eliminate malignant cells. This has resulted in...
4.
Verhoeff S, van de Donk P, Aarntzen E, Oosting S, Brouwers A, Miedema I, et al.
J Nucl Med
. 2022 May;
63(10):1523-1530.
PMID: 35512998
In this PD-L1 ImagiNg to prediCt durvalumab treatment response in SCCHN (PINCH) study, we performed Zr-DFO-durvalumab (anti-PD-L1 [programmed death ligand 1]) PET/CT in patients with recurrent or metastatic (R/M) squamous...
5.
van de Donk P, Wind T, Hooiveld-Noeken J, van der Veen E, Glaudemans A, Diepstra A, et al.
Eur J Nucl Med Mol Imaging
. 2021 Jun;
48(13):4369-4376.
PMID: 34076745
Purpose: Immune checkpoint inhibitors can induce a T cell-mediated anti-tumor immune response in patients with melanoma. Visualizing T cell activity using positron emission tomography (PET) might allow early insight into...
6.
van de Donk P, de Ruijter L, Lub-de Hooge M, Brouwers A, van der Wekken A, Oosting S, et al.
Theranostics
. 2020 Feb;
10(4):1708-1718.
PMID: 32042331
Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' immune system, resulting in...